EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Role of TRAIL in Apoptosis and Immunosurveillance in Cancer

Julio M Pimentel iD, Jun-Ying Zhou, Gen Sheng Wu

Cancers · 13.05.2023 · 15 (10) · 2752

DOI: 10.3390/cancers15102752 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 13.05.2023. Verfasst von Julio M Pimentel und 2 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Therapeutics Program, Karmanos Cancer Institute, School of Medicine, Wayne State University, Detroit, MI 48201, USA. Die Arbeit wurde bisher 120-mal zitiert (Crossref) und nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Institute of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily that selectively induces apoptosis in tumor cells without harming normal cells, making it an attractive agent for cancer therapy. TRAIL induces apoptosis by binding to and activating its death receptors DR4 and DR5. Several TRAIL-based treatments have been developed, including recombinant forms of TRAIL and its death receptor agonist antibodies, but the efficacy of TRAIL-based therapies in clinical trials is modest. In addition to inducing cancer cell apoptosis, TRAIL is expressed in immune cells and plays a critical role in tumor surveillance. Emerging evidence indicates that the TRAIL pathway may interact with immune checkpoint proteins, including programmed death-ligand 1 (PD-L1), to modulate PD-L1-based tumor immunotherapies. Therefore, understanding the interaction between TRAIL and the immune checkpoint PD-L1 will lead to the development of new strategies to improve TRAIL- and PD-L1-based therapies. This review discusses recent findings on TRAIL-based therapy, resistance, and its involvement in tumor immunosurveillance.

Schlagwörter

Stichwörter der Autor:innen

PD-L1TRAILapoptosisimmunosurveillanceresistance

Autor:innen und Institutionen

  • Molecular Therapeutics Program, Karmanos Cancer Institute, School of Medicine, Wayne State University, Detroit, MI 48201, USA.
  • Cancer Biology Program, School of Medicine, Wayne State University, Detroit, MI 48201, USA.
  • Department of Oncology, School of Medicine, Wayne State University, Detroit, MI 48201, USA.
  • Department of Pathology, School of Medicine, Wayne State University, Detroit, MI 48201, USA.

ORCID-Profile: Julio M Pimentel

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Institute of Health
  • NCI (National Cancer Institute) (GSW)
  • T32 Fellowship
  • Dean’s Diversity Fellowship of Wayne State University (JMP)

Zitieren

APA

Pimentel, J. M., Zhou, J. Y., & Wu, G. S. (2023). The Role of TRAIL in Apoptosis and Immunosurveillance in Cancer. Cancers, 15(10), 2752. https://doi.org/10.3390/cancers15102752

Vancouver

Pimentel JM, Zhou JY, Wu GS. The Role of TRAIL in Apoptosis and Immunosurveillance in Cancer. Cancers. 2023;15(10):2752. doi:10.3390/cancers15102752

BibTeX
@article{Pimentel2023,
  author = {Pimentel, Julio M and Zhou, Jun-Ying and Wu, Gen Sheng},
  title = {The Role of TRAIL in Apoptosis and Immunosurveillance in Cancer},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {10},
  pages = {2752},
  doi = {10.3390/cancers15102752}
}
Kostenlos starten →